Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

PURPOSE: To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800 mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic myeloid leukemia in chronic phase. PATIENTS AND METHODS: A total of 476 patients were randomly assigned 2:1 to imatinib 800...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Cortes, Jorge E., Baccarani, Michele, Guilhot, François, Druker, Brian J., Branford, Susan, Kim, Dong-Wook, Pane, Fabrizio, Pasquini, Ricardo, Goldberg, Stuart L., Kalaycio, Matt, Moiraghi, Beatriz, Rowe, Jacob M., Tothova, Elena, De Souza, Carmino, Rudoltz, Marc, Yu, Richard, Krahnke, Tillmann, Kantarjian, Hagop M., Radich, Jerald P., Hughes, Timothy P.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2010
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979244/
https://ncbi.nlm.nih.gov/pubmed/20008622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.3724
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items